Conference Call Summary, page-238

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 238 Last

Share
Profile

Follow
mumstheword

2,533 Posts.

272

11/08/17

09:26

Post #: 26434332
Share

Originally posted by MightyChina ↑

thanks for posing various questions in the CC amd writing back here. Far better calibre of investment forum posting than the nakedly greedy. All holders want it to do well, the question is the approach. Intellectual integrity in this regard (synonymous with critical thinking) is logically the most prudent posture. This can aid delineation of investment noise and signal, just as it does in terms of robust sound engineering of the ED noise vs signal issue, as well as spurious cough from a parent or nurse.

I worry about the way this forum platform appears slanted to positive bias. There is no red arrow. Perhaps there should be no green tick? Way too many people get burned here. It isn't kind, even if those very people were the types to mock dissenters right before the immolation of their investment.

In terms of confidence intervals, the wording in the CC should be noted. It sounded like the view that they weren't necessary could be taken several ways. The way I understood that to mean was not necessary for progression to FDA. They were worked out internally and yes, availability of that data would be nice.

I may not post for much longer, not sure it is worth it in the Australian jurisdiction.

Expand

Thats a shame if you cant continue to post. Your posts have been constructive and provided balance. Same - same with Red Bar... I understood he's cut n run.

RAP Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 339 more messages in this thread...

First 238 Last

Add RAP (ASX) to my watchlist

Conference Call Summary, page-238

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News